CAR-T deaths prompt halt by Novartis; Eli Lilly’s 13th acquisition of 2026; and more
Welcome back to Endpoints Weekly. Endpoints News broke the news this week on the deaths of three patients who received Novartis’ experimental CAR-T therapy. Novartis has paused immunology and neuroscience studies for the drug, and ...
Novartis and Bristol Myers Squibb have halted multiple trials of their cell therapy programs for autoimmune conditions due to inflammatory side effects observed during testing. According to BioPharma Dive, Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment, and side effect management could help developers avoid future safety hazards.
The trials in question involve CAR-T cell therapies, which are being evaluated for their potential to treat autoimmune conditions. The decision to pause the trials was made after inflammatory side effects were observed in patients undergoing treatment.
The development has raised questions about the future of autoimmune CAR-T therapies. Analysts are suggesting that developers take a more cautious approach to mitigate potential safety risks.
Brief written by urgent.news from BioPharma Dive, STAT News — 2 reports on this story. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
